A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2023-05-21
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-11-16 (study day 159); relationship: not assessed
severe
assessed
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-06 (study day 270); relationship: N
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-03-25 (study day 289); relationship: not assessed
Data queries
No data queries.